BNP Paribas Asset Management’s Nektar Therapeutics NKTR Stock Holding History

BNP Paribas Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.7K	Buy	469 +72	+18%	+$5.27K	﹤0.01%	1919
2026 Q1	$28.6K	Buy	397 +219	+123%	+$12.5K	﹤0.01%	1917
2025 Q4	$8K	Buy	+178	New	+$9.96K	﹤0.01%	2222
2019 Q3	–	Sell	-397	Closed	-$212K	–	870
2019 Q2	$212K	Buy	+397	New	+$199K	﹤0.01%	879
2019 Q1	–	Sell	-678	Closed	-$342K	–	932
2018 Q4	$342K	Hold	678	–	–	﹤0.01%	835
2018 Q3	$620K	Sell	678 -575	-46%	-$491K	﹤0.01%	768
2018 Q2	$918K	Buy	+1,253	New	+$1.44M	0.01%	753

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's NKTR Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Nektar Therapeutics (NKTR) stake by 18% in Q2 2026, buying an estimated $5.27K and bringing the position to 469 shares worth $32.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1919.

BNP Paribas Asset Management first reported a position in NKTR in Q2 2018 and has held it in 7 quarters since. The position peaked at $918K in Q2 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

BNP Paribas Asset Management held 469 shares of Nektar Therapeutics worth $32.7K as of Q2 2026.
BNP Paribas Asset Management bought 72 Nektar Therapeutics shares in Q2 2026, an estimated $5.27K.
Nektar Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1919 holding.
BNP Paribas Asset Management first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 7 quarters since.
BNP Paribas Asset Management's Nektar Therapeutics position peaked at $918K in Q2 2018.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.